Content
03/27/2025
Miami, FL USA
Galatea Bio
completed $25 million Venture Round funding. Investors include
F-Prime Capital, Helios Investment Partners, Digitalis Ventures, AME Cloud Ventures, CEI Ventures, Alexandria Venture Investments, HBM Genomics, Stanford University.
About
Galatea Bio is a biotechnology company advancing precision medicine through AI-driven data analytics and genomic research on large-scale patient populations, enriched in non-European ancestry. By integrating clinical genomics, a proprietary biobank, and AI-enabled algorithms, Galatea Bio accelerates biomarker and drug target discovery, enhances clinical diagnostics, and supports biopharma partnerships. With a global network spanning research institutions, healthcare providers, and pharmaceutical companies, Galatea Bio develops ancestry-informed diagnostics and data solutions that improve patient outcomes and drive therapeutic innovation.
Startup
Sector:
Biotech
Life Science
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
